Cargando…
Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has infected over 260 million people over the past 2 years. Remdesivir (RDV, VEKLURY®) is currently the only antiviral therapy fully approved by the FDA for the treatment of COVID-19. The pare...
Autores principales: | Pitts, Jared, Babusis, Darius, Vermillion, Meghan S., Subramanian, Raju, Barrett, Kim, Lye, Diane, Ma, Bin, Zhao, Xiaofeng, Riola, Nicholas, Xie, Xuping, Kajon, Adriana, Lu, Xianghan, Bannister, Roy, Shi, Pei-Yong, Toteva, Maria, Porter, Danielle P., Smith, Bill J., Cihlar, Tomas, Mackman, Richard, Bilello, John P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068261/ https://www.ncbi.nlm.nih.gov/pubmed/35525335 http://dx.doi.org/10.1016/j.antiviral.2022.105329 |
Ejemplares similares
-
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022) -
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021) -
Pharmacokinetics of Orally Administered GS-441524 in Dogs
por: Yan, Victoria C., et al.
Publicado: (2021) -
539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
por: Pitts, Jared, et al.
Publicado: (2023) -
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
por: Vermillion, Meghan S., et al.
Publicado: (2021)